Platelet-rich plasma (PRP) has been suggested as an adjunct to aid in long-bone healing. The purpose of this study was to systematically review the basic science in vivo evidence for the use of PRP in the treatment of bone pathology. The PubMed/MEDLINE and EMBASE databases were screened using the following search criteria: "(Platelet-rich plasma OR PRP OR autologous conditioned plasma OR ACP) AND (bone OR osteocytes OR osteogenesis OR nonunion OR delayed union)." Studies were included if they fulfilled the following criteria: (1) studied the effect of PRP or a similar concentrated platelet product, defined as a blood product with platelet concentration elevated to higher than baseline; (2) established a control with which to compare PRP; (3) were published in a peer-reviewed journal; and (4) looked specifically at animal long-bone models. All review articles and clinical studies, including randomized controlled trials and case series, were excluded from the review. Studies examining the effects of PRP on bones of animals with confounding pathology were excluded. In studies that contained additional treatment variables, only the portion of the experiment that compared PRP directly with the control were evaluated. Data were then extracted with a standardized table. The search yielded 29 articles for inclusion. Seventy-two percent of the studies reported platelet concentrations. Eighty-nine percent of studies reported significant improvement in earlier bone healing on histologic/histomorphometric assessment. One hundred percent showed significant increase in bone formation on radiographs in the PRP group. Eighty percent of studies reported a significant increase in bone area on microcomputed tomography. One hundred percent of studies showed a higher torsional stiffness for the PRP-treated defects. In the in vivo studies evaluated, PRP confers several beneficial effects on animal long-bone models. Proof of concept for PRP as a biologic adjunct in long-bone models has been determined.
A lthough the majority of fractures heal uneventfully, it has been reported that 5% to 10% of all fractures either fail to heal or demonstrate a delay in healing. 1 This failure can result in multiple surgeries, leading to increased morbidity, lost work days, and increased health care costs. Therefore, there has been an increased need to develop therapeutic strategies that improve bone healing and accelerate bone repair to prevent malunion, nonunion, and delayed union. 2 Platelet-rich plasma (PRP) is currently used in several orthopedic pathologies of cartilage, tendon, ligaments, and bone. The interest in PRP is particularly heightened among practitioners because it is an autologous biologic that may be a conservative alternative or adjuvant to standard surgical treatments. Whether used conservatively or intraoperatively, PRP functions to stimulate the regeneration of low-intrinsic-healing-potential tissue. 3 Platelet-rich plasma is an autologous concentrate of platelets obtained directly from the peripheral venous blood of the patient, which is produced by the centrifugation of whole blood, thereby yielding a concentration of platelets that is increased to higher than baseline values. 4 The advantage of PRP is that it contains many growth factors that have been shown to enhance osteogenesis. Plateletderived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor-2 (FGF-2) have been shown to stimulate osteoblastic progenitor cell proliferation, whereas VEGF and FGF-2 have improved angiogenesis and revascularization in bone pathology. 5 The many chemokines and cytokines contained in the alpha granules of platelets concentrated in PRP also play an important role in healing, stimulating chemotaxis, and cell proliferation and maturation. 6 Several studies have suggested that in the proper osteogenic environment, PRP may increase the proliferation of osteoblastic cells and matrix synthesis as well as promote fibroblastic growth, differentiation, and scar formation. A proof of concept that PRP is osteogenic must be established from preclinical evidence.
Current Level I clinical evidence for the use of PRP in bone healing is minimal and includes mixed results. For PRP to gain widespread acceptance as an evidence-based treatment modality for bone pathology, large-scale randomized controlled clinical trials (RCTs) of high methodologic quality must be conducted.
The goal of the current study was to systematically review the basic science evidence for the investigation of PRP in pathologic processes of animal long bone. It was hypothesized that the majority of basic science literature would show that PRP confers multiple potential benefits identifiable on histological, radiographic, and biomechanical analysis of animal bone models when compared with a control. However, the authors hypothesized that the majority of these effects may not be identified on gross morphology.
Materials and Methods

Literature Search
Using the terms "(platelet-rich plasma OR PRP or autologous conditioned plasma OR ACP) AND (bone OR osteocyte OR osteogenesis OR nonunion OR delayed union)," the authors searched the PubMed/MEDLINE and EMBASE electronic databases in June 2014. The reference lists of included studies were also reviewed and compared with the collected studies to ensure no pertinent articles were omitted. 
Inclusion Criteria
Studies were included if they fulfilled the following criteria: (1) studied the effect of PRP or a similar concentrated platelet product, defined as a blood product with platelet concentration elevated to higher than baseline; (2) established a control with which to compare PRP; (3) published in a peer-reviewed journal; and (4) looked specifically at animal long-bone models. All review articles and clinical studies, including RCTs and case series, were excluded from the review. Studies examining the effects of PRP on bones of animals with confounding pathology were excluded. In studies that contained additional treatment variables, only the portion of the experiment that compared PRP directly with the control were evaluated. Only studies written on various preparations and treatment modalities for PRP were included for review, such as single-and twice-centrifuged PRP, calcium chloride-and thrombinactivated PRP, PRP injections, PRP gels, and releasates from PRP clots.
One author (A.G.) performed the literature search, and 3 authors (A.G., L.Z., I.S.-E.) independently reviewed the search results. The title and abstract were reviewed for all search results, and potentially eligible studies received full-text review. All 3 assessing authors agreed on studies meeting criteria for inclusion.
Data Extraction
A standardized data sheet was developed, and 2 authors (A.G., I.S.-E.) extracted pertinent information, including PRP preparation and cytology, type of species, number of animals, type of bone used, size of bone defect, groups compared, time periods analyzed, type of evaluation, and results. Once the data collection process was complete, data were analyzed for trends in outcomes comparing and contrasting the effects of PRP reported in the literature.
Quality of Evidence
There was no quality threshold for inclusion. The authors were interested in the effects of reported study quality, and they analyzed differences in reported efficacy among studies. They analyzed quality of evidence by modifying the previously reported 10-item study quality checklist. 7 Their modified checklist comprised the following 9 criteria: (1) publication in a peer-reviewed journal; (2) statement of PRP concentration; (3) control group; (4) randomization to treatment or control; (5) blinded assessment of outcome; (6) statement of animal sex; (7) use of animals with no underlying pathology; (8) sample size calculation; and (9) statement regarding possible conflicts of interest. The final quality score was calculated by adding each scored checklist item. The analyses to be performed were specified in advance of any data collection. 8 
Statistical Analysis
The magnitude of the effect of PRP was quantified by comparing radiographic and histologic/histomorphometric outcomes between PRP and scaffold vs scaffold-only groups and PRP vs control groups. Results are presented as Hedges' g standardized effect sizes with 95% confidence intervals (CIs) (Figure 1 ).
results
Search and Literature Selection
The search parameters yielded 1620 results from PubMed/MEDLINE and 2272 results from EMBASE ( Figure  2) . 10 After duplicates were excluded and abstracts were reviewed, 57 studies fit the inclusion criteria for review. The full-text review yielded 29 articles that fit the inclusion criteria ( Table 1) . Twenty-eight articles were excluded because they studied tissue and cells not relevant to bone repair, did not control for PRP administration, or studied several variables without an emphasis on PRP alone against a control. 
Study Quality
Twenty-nine (100%) of 29 studies were published in peer-reviewed journals.
5,11-38 Only 9 (31%) reported randomization. 12, 16, 19, 22, 23, 27, 28, 32, 36 Ten (34%) stated no conflict of interest. No study described a sample size calculation. The median quality score was 6.07 (range, [4] [5] [6] [7] [8] . Although this compares favorably with similar systematic reviews, it can still represent potential for possible publication bias ( Table 2) .
Evaluation of Platelet-Rich Plasma Preparation
Multiple animal models were used, including rabbit, rat, dog, sheep, and goat. Long-bone sites included femur, tibia, radius, and ulna. Of the 29 studies, 29 (100%) reported the preparation of PRP (Table 1) . 5, Twenty-one (72%) of the 29 studies reported either platelet concentrations or percentage increase of platelet concentration ( Table  1) . 5, 13, 14, 16, 17, [20] [21] [22] [23] [24] [25] 27, 29, [31] [32] [33] [34] [35] [36] [37] [38] All showed that platelet levels were significantly higher than whole blood. One (3%) study reported CD4+ and CD8+ levels for PRP, 38 and 1 (3%) study reported leukocyte and fibrinogen counts. 27 Three (10%) studies analyzed PRP for growth factors, which included PDGF, transforming growth factor-beta 1 (TGF-ß1), and VEGF. 16, 20, 35 
Evaluation of Animal Models
Fourteen (48%) of the 29 studies used a white rabbit model. Of the rabbit studies, 5 investigated the femur, 12,14,24-26 4 investigated the tibia, 11, 21, 28, 30 and 5 investigated the radius. 18, 22, 23, 32, 38 Four (14%) studies used a rat model, 3 of which investigated the femur 5,15,35 and 1 of which investigated the tibia. 37 Four (14%) studies used a canine model, investigating 1 femur, 19 1 tibia, 13 1 radius, 36 and 1 ulna. 33 Four (14%) studies used a sheep model: 2 investigated the tibia, 31 ,34 1 investigated the femur, 17 and 1 investigated both the femur and the tibia. 27 Two (7%) studies used a pig model, and both investigated the tibia (Table 1) . 16, 20 
Evaluation of Outcomes
Results of the studies are shown in Table 3 . Of the 29 studies, 29 (100%) performed either a histologic or histomorphometric assessment of the treated and control bone defects, using hematoxylineosin stain, immunostaining, or both. 5, Of these 29 studies, 18 (62%) performed statistical analysis. Sixteen (89%) of the 18 studies showed statistically significant improvements in either earlier bone healing, higher tissue differentiation rates, or higher rates of bone regeneration. [13] [14] [15] [16] [20] [21] [22] [23] [24] [25] [26] [27] 30, 32, 37, 38 Of the 11 studies that did not report statistics, 9 (82%) showed qualitative improved bone healing. 5, 11, 18, 19, 28, 29, 31, 35, 36 Of the 29 studies, 15 (52%) performed a radiologic assessment of the treated and control bone defects. 16, 18, 20, 21, 23, [27] [28] [29] [31] [32] [33] [34] [35] [36] 38 Of these 15 studies, 6 (40%) reported statistical analyses. 21, 27, 28, 32, 35, 36 One hundred percent of these reported a significant increase in the amount of consolidation and bone formation, as well as greater cortical bone thickness, in the PRP group. Seven (78%) of 9 studies reported a nonstatistical qualitative improvement in bone consolidation. 16, 18, 20, 23, 29, 31, 38 Six (21%) studies performed an assessment using microcomputed tomography to observe bone formation. 5, 17, 22, 25, 27, 34 Of the 5 studies that calculated statistics, 4 (80%) reported a statistically significant increase in bone area and bone formation. 5, 22, 27, 34 One study did not use statistical analysis but showed improvement. 25 Six (21%) studies investigated the biomechanical properties, primarily focusing on torsion and torque. 5, 15, 22, 32, 34, 35 Of these 6 studies, 5 (83%) performed statistical analysis. One hundred percent of the 5 studies reported a significantly higher torsional stiffness for the PRP-treated defects. 5, 15, 22, 32, 35 One of these studies looked at bone strength and bone depth and reported a significant increase in 3-point load bearing resulting in an increased bone strength following PRP treatment. 35 Four (14%) studies used dual-energy X-ray absorptiometry (DEXA) to access bone mineral density 18, 34, 36, 38 ; 3 (75%) of these reported a statistically significant increase in bone density in the PRP group. 18, 36, 38 One (25%) study reported no difference between the 2 groups. 34 Three (10%) studies performed a gross assessment of bone healing, 21, 29, 32 one (33%) of which reported a statistically significant improvement 32 and 2 (66%) of which reported a nonstatistically significant improvement. 21, 29 One study (3%) reported statistically significant improvements in bone ingrowth depth and osteoblast shape and density, 27 and one study (3%) reported statistically significant bone healing based on radionuclide scans.
38
Statistical Evaluation
Of the 29 studies, 29 (100%) performed either a histologic or histomorphometric assessment. 5, Only 18 (62%) of these studies reported full quantitative results with all means and SDs. [12] [13] [14] [15] [16] [17] [20] [21] [22] [23] [24] [25] [26] [27] 30, 32, 37, 38 The other 11 (38%) reported their results as descriptions, graphs, selectively reported means, or means without SDs. For radiographs, 6 (40%) of 15 studies performed a form of numerically based analysis. 20, 21, 27, 28, 32, 36 The time frame of study analysis varied widely. To adequately compare modalities, the authors needed to identify time points consistent across different studies; a 4-to 12-week range captured the most studies. To perform a standardized mean difference across studies, the authors identified studies that fell in this time frame and reported numerical analysis with all means and SDs for the groups and modalities compared. Studies that reported their findings in graphs, selectively reported means, or lacked SDs were excluded from analysis after attempts were made to contact corresponding authors. The authors identified studies with histological and histomorphological analysis, and 6 studies with radiographic analysis were deemed eligible for comparison. Figure 3 and Figure 4 show standardized mean differences in radiographic and histologic/histomorphometric modalities at 4 to 12 weeks between pairs of treatment groups, along with 95% CIs. Effect sizes were predominantly positive for PRP+scaffold vs scaffold and PRP vs control, with wide variability in the strength of effect.
discussion
The in vivo basic science literature indicates that PRP has several potential effects in the repair of animal long-bone de- n Feature Article fects compared with controls. Most studies concluded that PRP-treated bone defects showed more advanced time to bone healing than the control group. Sixteen (89%) of the 18 studies that performed statistical analysis showed improved bone regeneration in the PRP-treated group. Nather et al 30 reported that osteoid bridging of the gap at host-graft junctions occurred 12 weeks earlier in the autograft and allograft-with-PRP groups compared with the control groups. In comparison, bone union was significantly delayed in the allografts without PRP. 30 Parizi et al 32 found that the coral-platelet group was superior to the control group histologically. In the control group, fibrous nonunions were found in the osseous defects and were poorly revascularized. Bridging callus or histological union did not develop in any of these defects, leading to a slower healing process in the control group. 32 It has been well established that platelets play a physiological role in healing and have been used in other medical fields, such as oral and maxillofacial surgery, to enhance bone and soft tissue healing. Marx et al 39 presented a model of mandibular bone graft regeneration, illustrating the mechanism by which PRP may enhance bone regeneration both in rate and amount. Surgical sites having received PRP have been shown to heal at a rate 2 to 3 times higher than sites without PRP application. 39 The multitude of growth factors that are stored within the platelets' alpha granules are thought to enhance the biological environment. 40 These polypeptides influence cell population, differentiation, and matrix production in cell and organ culture, all processes involved in fracture healing. These growth factors modulate the bone regenerative effect of PRP and include PDGF, insulinlike growth factor (IGF), and TGF-ß. 39 In addition, 2 members of the TGF-ß superfamily, TGF-ß1 and bone morphogenic proteins (BMPs), trigger osteoblastic differentiation as well as the production of new bone marrow matrix. 41 Therefore, the components that compose PRP result in enhanced bone healing and regeneration, leading to improved osteoid bridging and bone union.
Radiographic findings demonstrated greater osseous bridging of the defects in the PRP group when compared with the controls. In a study by Souza et al, 36 radiographs were assessed by a modified grading score of 0 to 6. This score was determined by the size of the fracture line, whether there was proliferation of bone, and the amount of callus bridging. 36 They reported that in the PRP group, the median radiographic score for healing increased significantly between day 0 (score 0) and day 60 (score 5). At 60 days, the median healing score and the proportion of healed osteotomies in the control group (score 1; 1/6 healed) and PRP group (score 5; 4/5 healed) were significantly different. 36 The authors hypothesized that this improved healing may be attributed to PRP's influence on mitogenesis and chemotaxis for both fibroblasts and osteoblasts. 24 In addition, PDGF has been shown to stimulate bone formation and consistently enhance wound fill, resulting in enhanced bone regeneration. Transforming growth factor-ß has also been implicated to have a role in the stimulation of mesenchymal stem cell (MSC) proliferation and subsequent osteogenic differentiation. 42 In general, these factors influence cell mitosis and collagenous and noncollagenous protein synthesis to modulate the cells in callus as they progress through the stages of healing. 43 Although several studies demonstrated effects of PRP in isolation, it was also demonstrated that PRP improved bone healing when used with a scaffold. Kasten et al 22 reported results with calcium phosphates in which the addition of PRP to hyaluronic acid (HA) improved bone defects in rabbits. They reported increased bone formation on microcomputed tomography in the PRP group, with a 24.8%±5.5% increase in total CDHA cylinder volume compared with 11%±3.6% in the control group of CDHA alone (P<.05). 22 Kanthan et al 21 reported improved healing of segmental defects in rabbits when combined with a coral-based osteoconductive scaffold. Statistical analysis demonstrated significant differences in bone healing between individual groups based on radiological, histological, and gross findings. Kanthan et al 21 used a scoring system described by Cheung et al 44 and reported that the mean radiologic score was highest in the Corograft+PRP group compared with all other groups (control [no PRP or Corograft], PRP alone, and Corograft alone). In addition, the Corograft+PRP group showed higher amounts of calcium deposition on Alizarin Red stains on histological sections. The authors hypothesized that the scaffold assisted in localizing the cell-signaling molecules released by the platelets in PRP that may promote osteogenesis. 21 Although type II collagen is primarily cartilaginous, studies have shown that it plays a vital role in the formation of long bones via endochondral ossification. Smyth et al 40 noted that the addition of PRP resulted in higher International Cartilage Repair Society (ICRS) histological scores following autologous osteochondral transplantion in a rabbit model at 3, 6, and 12 weeks postoperatively (P=.002). In the study, the macroscopic appearance did not change significantly between the PRP group and control (P=.09). The authors speculated that PRP may mediate interleukin-1 (IL-1)-mediated upregulation of matrix metalloproteinases (MMPs), thereby inhibiting catabolic processes leading to tissue breakdown. 40 Van Buul et al 45 found that PRP decreased IL-1ß-mediated inhibition of type II collagen and aggrecan gene expression and also decreased the IL-1ß-induced increase of ADAMTS4 and PTGS2 gene expression. Interleukin-1ß is a catabolic cytokine, which increases the activity and levels of ADAMTS, a metalloproteinase. 46 Lippross et al 47 found that the administration of PRP caused moderate recovery of type II collagen lost to inflammation and also reduced IL-ß levels. This recovery of type II collagen by PRP may be relevant to collagen II recovery in long bones.
Platelet-rich plasma not only had potentially beneficial influences on the rate of healing and histological quality of osseous repair, but it also influenced the biomechanic quality of the bone. Five of 6 studies showed increased torsion and torque as well as an increase in load bearing and bone strength. This may be beneficial in the clinical setting with regard to rehabilitation of the bone injury. Earlier weight bearing and mobilization are associated with fewer adhesions, increased postoperative range of motion, earlier return to activity, and greater patient satisfaction. 48 Rai et al 5 noted that although they found a higher percentage of bone union, defined as the bridging of the defect with mineralized matrix, this does not necessarily result in functional restoration. They reported that PRPtreated femurs possessed significantly higher stiffness (0.0049±0.003 Nm/deg) than controls (0.0036±0.003 Nm/deg). 5 They noted that the mechanical properties of the repaired femurs were still substantially less than those of intact bone. An explanation for this finding was that the new bone was immature and in its first stage of remodeling, thus necessitating studies with longer-term follow-up. 5 There are several limitations to the in vivo literature currently available on the use of PRP in osseous pathology, including inconsistencies in the evidence and differences in the type of PRP used. Importantly, an inherent disadvantage of in vivo studies is the limitation of the transferability of results to clinical practice. Several studies included in this review studied a critical size defect in the long bones of rabbits, rats, sheep, goats, pigs, and canines. Although these models are appropriate for evaluation of bone regeneration, limited data exist evaluating which model is most similar to a human model. 49 Chosen animal models should demonstrate physiological and pathophysiological analogies, which may aid in the transferability of conclusions to humans. 50 Studies using pig models have reported similar anatomical and morphological features to that of human bone regeneration, including healing capacity and bone mineral density and concentration. 16, 20, [50] [51] [52] In addition, the bone growth rate of pigs is approximately 1.2 to 1.5 mm per day, which is similar to the osseous reparative capacity of humans. 20 The current study focused on the effects of PRP on the animal long-bone model. Long-bone development results from endochondral ossification from hya-line cartilage. It would be difficult to include other types of bones, such as the flat bones in a calvarial model, because development results from intramembranous ossification from fibrous membranes. To combine long-bone and calvarial models would confound any meaningful outcomes.
The results of this study demonstrate that there may be a beneficial influence of PRP on bone healing; however, there were controversies within the literature. Four studies showed no effect of PRP on histologic bone regeneration. A discrepancy in this outcome may be due to the fact that all PRP systems are not created equally and that the variation of platelet concentration may play a role in conflicting results. 24 Only 16 (55%) of 29 studies reported the platelet count and/or concentration, and none of the studies reported white blood cell and red blood cell counts. Furthermore, although 5 (17%) of 29 studies made reference to the amount of increase in platelet concentration compared with the control, 8 (28%) of 29 made no mention of the platelet concentration of the PRP. The current study attempted wherever possible to identify whether the product was neutrophil depleted, but beyond that, PRP is not amenable to characterization based on available data from the literature. It was not possible to accurately draw conclusions on the effect of the varying concentrations of the constituents of PRP due to this lack of reporting.
Another limitation of this study was the difference in centrifugation systems used. Platelet-rich plasma is not a standardized preparation, regardless of what commercial system is used. Castillo et al 53 found that the contents of PRP vary significantly depending on which system is used. In addition, there has been no set definition that defines the composition of PRP. It is possible to have both inter-and intraindividual variability. Therefore, a basic cytologic analysis of PRP is necessary in the description of PRP to accurately compare the results of different studies.
DeLong et al 54 developed a classification system for reporting PRP composition based on platelet concentration, the activation method used, and the white cell count of the PRP, yielding the acronym PAW. This study 54 attempted to identify what PRP system was used. Based on the limited reporting of these critical PRP components, a classification such as PAW should be implemented to collect data for the comparison of the effects of PRP between studies. The effect of leukocyte content in the clinical setting is still unknown and is an important area of study. 54 In addition, other factors that should be taken into consideration include the critical size of the defects, the vascularization of cancellous bone, whether PRP was used in combination with autograft or a matrix, and the platelet concentration.
Failure of PRP to produce consistent increases in bone formation and osseointegration in vivo could also be due to the variability in the number of platelets, leukocytes, and growth factors from preparations from the same individual that is not system dependent. Boswell et al 55 attributed this variation to a number of factors, including hydration status, inflammation, lipemia, or circadian rhythms in platelet numbers. They also found that concentration failure could occur when using one system but may be successful with a different system in some individuals. Therefore, individual differences in platelet-concentrating capabilities may be dependent on the system used. 55 Although there are many studies on the bone-healing potential of PRP, adequate cross-study comparison is difficult to make. The current authors report that although 29 studies performed numerical histological analysis, only 11 studies were suitable for cross-study comparison. Similarly, only 8 of 15 studies were suitable for radiographic comparison. The studies chosen were suitable for cross-study comparison due to their analysis being performed during similar time frames, using similar modalities with numerical results and full reports of all means and SDs. Although the bone-healing potential of PRP is elucidated, measuring PRP's effect size is difficult without standardization across studies. Areas suitable for standardization identified in this review are time frame for analysis, histological and radiographic criteria to be evaluated, and histological and radiographic criteria necessary to deem a defect fully healed.
It is also important to note that all of the included in vivo studies analyzed the effects of PRP on only surgically created acute lesions in the bone. In most cases, the lesions were immediately treated with PRP before closure. In clinical practice, delayed union is a chronic condition that cannot be easily replicated in an animal model. Future in vivo research on PRP examining more chronic bone pathologies is warranted.
conclusion
The current basic science evidence suggests that PRP has several potential beneficial effects on animal long-bone repair and bone healing. These benefits have been identified through radiographic, histologic, and biomechanical analysis. Proof of concept has been established for PRP in treatment of bone defects. Welldesigned RCTs are needed to extrapolate this evidence to clinical settings. Methods of reporting PRP preparation, platelet concentration, and cell cytology have been inconsistent among evaluated studies, and the lack of consistency in the analysis of bone healing between different modalities and within each modality warrants further standardization.
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